Treatment of dysarthria following subthalamic nucleus deep brain stimulation for Parkinson's disease
Identifieur interne : 001766 ( Main/Corpus ); précédent : 001765; suivant : 001767Treatment of dysarthria following subthalamic nucleus deep brain stimulation for Parkinson's disease
Auteurs : Elina Tripoliti ; Laura Strong ; Freya Hickey ; Tom Foltynie ; Ludvic Zrinzo ; Joseph Candelario ; Marwan Hariz ; Patricia LimousinSource :
- Movement Disorders [ 0885-3185 ] ; 2011-11.
English descriptors
- KwdEn :
Abstract
Background:: Deep brain stimulation of the subthalamic nucleus (STN‐DBS) is an established treatment for patients with Parkinson's disease (PD). Speech impairment is a frequent side effect of the surgery. This study examined the efficacy of an intensive speech treatment, the Lee Silverman Voice Treatment (LSVT) on dysarthria after STN‐DBS. Methods:: The LSVT was administered to 10 patients with STN‐DBS (surgical group) and 10 patients without (medical group). Patients were assessed before, immediately after, and 6 months following the speech treatment using sustained phonation, a speech intelligibility scale, and monologue. Vocal loudness, speech intelligibility, and perceptual ratings were the primary outcome measures. Results:: Vocal loudness and perceptual scores improved significantly across tasks for the medical group only. Speech intelligibility did not significantly change for either group. Results in the surgical group were variable, with some patients deteriorating. Conclusions:: Treatment of dysarthria following STN‐DBS needs further investigation because of the variable response to LSVT. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23887
Links to Exploration step
ISTEX:12A5E4E8257155C2B556028FF95ECCC9859A26B3Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of dysarthria following subthalamic nucleus deep brain stimulation for Parkinson's disease</title><author><name sortKey="Tripoliti, Elina" sort="Tripoliti, Elina" uniqKey="Tripoliti E" first="Elina" last="Tripoliti">Elina Tripoliti</name><affiliation><mods:affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Strong, Laura" sort="Strong, Laura" uniqKey="Strong L" first="Laura" last="Strong">Laura Strong</name><affiliation><mods:affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Hickey, Freya" sort="Hickey, Freya" uniqKey="Hickey F" first="Freya" last="Hickey">Freya Hickey</name><affiliation><mods:affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Foltynie, Tom" sort="Foltynie, Tom" uniqKey="Foltynie T" first="Tom" last="Foltynie">Tom Foltynie</name><affiliation><mods:affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Zrinzo, Ludvic" sort="Zrinzo, Ludvic" uniqKey="Zrinzo L" first="Ludvic" last="Zrinzo">Ludvic Zrinzo</name><affiliation><mods:affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Candelario, Joseph" sort="Candelario, Joseph" uniqKey="Candelario J" first="Joseph" last="Candelario">Joseph Candelario</name><affiliation><mods:affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Hariz, Marwan" sort="Hariz, Marwan" uniqKey="Hariz M" first="Marwan" last="Hariz">Marwan Hariz</name><affiliation><mods:affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Limousin, Patricia" sort="Limousin, Patricia" uniqKey="Limousin P" first="Patricia" last="Limousin">Patricia Limousin</name><affiliation><mods:affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:12A5E4E8257155C2B556028FF95ECCC9859A26B3</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23887</idno><idno type="url">https://api.istex.fr/document/12A5E4E8257155C2B556028FF95ECCC9859A26B3/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001766</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Treatment of dysarthria following subthalamic nucleus deep brain stimulation for Parkinson's disease</title><author><name sortKey="Tripoliti, Elina" sort="Tripoliti, Elina" uniqKey="Tripoliti E" first="Elina" last="Tripoliti">Elina Tripoliti</name><affiliation><mods:affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Strong, Laura" sort="Strong, Laura" uniqKey="Strong L" first="Laura" last="Strong">Laura Strong</name><affiliation><mods:affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Hickey, Freya" sort="Hickey, Freya" uniqKey="Hickey F" first="Freya" last="Hickey">Freya Hickey</name><affiliation><mods:affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Foltynie, Tom" sort="Foltynie, Tom" uniqKey="Foltynie T" first="Tom" last="Foltynie">Tom Foltynie</name><affiliation><mods:affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Zrinzo, Ludvic" sort="Zrinzo, Ludvic" uniqKey="Zrinzo L" first="Ludvic" last="Zrinzo">Ludvic Zrinzo</name><affiliation><mods:affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Candelario, Joseph" sort="Candelario, Joseph" uniqKey="Candelario J" first="Joseph" last="Candelario">Joseph Candelario</name><affiliation><mods:affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Hariz, Marwan" sort="Hariz, Marwan" uniqKey="Hariz M" first="Marwan" last="Hariz">Marwan Hariz</name><affiliation><mods:affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Limousin, Patricia" sort="Limousin, Patricia" uniqKey="Limousin P" first="Patricia" last="Limousin">Patricia Limousin</name><affiliation><mods:affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-11">2011-11</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">13</biblScope><biblScope unit="page" from="2434">2434</biblScope><biblScope unit="page" to="2436">2436</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">12A5E4E8257155C2B556028FF95ECCC9859A26B3</idno><idno type="DOI">10.1002/mds.23887</idno><idno type="ArticleID">MDS23887</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>LSVT</term><term>Parkinson's disease</term><term>STN‐DBS</term><term>speech</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background:: Deep brain stimulation of the subthalamic nucleus (STN‐DBS) is an established treatment for patients with Parkinson's disease (PD). Speech impairment is a frequent side effect of the surgery. This study examined the efficacy of an intensive speech treatment, the Lee Silverman Voice Treatment (LSVT) on dysarthria after STN‐DBS. Methods:: The LSVT was administered to 10 patients with STN‐DBS (surgical group) and 10 patients without (medical group). Patients were assessed before, immediately after, and 6 months following the speech treatment using sustained phonation, a speech intelligibility scale, and monologue. Vocal loudness, speech intelligibility, and perceptual ratings were the primary outcome measures. Results:: Vocal loudness and perceptual scores improved significantly across tasks for the medical group only. Speech intelligibility did not significantly change for either group. Results in the surgical group were variable, with some patients deteriorating. Conclusions:: Treatment of dysarthria following STN‐DBS needs further investigation because of the variable response to LSVT. © 2011 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Elina Tripoliti PhD</name><affiliations><json:string>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Laura Strong BSc</name><affiliations><json:string>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Freya Hickey BSc</name><affiliations><json:string>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Tom Foltynie MD, PhD</name><affiliations><json:string>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Ludvic Zrinzo</name><affiliations><json:string>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Joseph Candelario BSc</name><affiliations><json:string>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Marwan Hariz MD PhD</name><affiliations><json:string>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Patricia Limousin MD PhD</name><affiliations><json:string>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>speech</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>LSVT</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>STN‐DBS</value></json:item></subject><articleId><json:string>MDS23887</json:string></articleId><language><json:string>eng</json:string></language><abstract>Background:: Deep brain stimulation of the subthalamic nucleus (STN‐DBS) is an established treatment for patients with Parkinson's disease (PD). Speech impairment is a frequent side effect of the surgery. This study examined the efficacy of an intensive speech treatment, the Lee Silverman Voice Treatment (LSVT) on dysarthria after STN‐DBS. Methods:: The LSVT was administered to 10 patients with STN‐DBS (surgical group) and 10 patients without (medical group). Patients were assessed before, immediately after, and 6 months following the speech treatment using sustained phonation, a speech intelligibility scale, and monologue. Vocal loudness, speech intelligibility, and perceptual ratings were the primary outcome measures. Results:: Vocal loudness and perceptual scores improved significantly across tasks for the medical group only. Speech intelligibility did not significantly change for either group. Results in the surgical group were variable, with some patients deteriorating. Conclusions:: Treatment of dysarthria following STN‐DBS needs further investigation because of the variable response to LSVT. © 2011 Movement Disorder Society</abstract><qualityIndicators><score>6.884</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>4</keywordCount><abstractCharCount>1148</abstractCharCount><pdfWordCount>14214</pdfWordCount><pdfCharCount>97058</pdfCharCount><pdfPageCount>23</pdfPageCount><abstractWordCount>157</abstractWordCount></qualityIndicators><title>Treatment of dysarthria following subthalamic nucleus deep brain stimulation for Parkinson's disease</title><genre><json:string>article</json:string></genre><host><volume>26</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>3</total><last>2436</last><first>2434</first></pages><issn><json:string>0885-3185</json:string></issn><issue>13</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1002/mds.23887</json:string></doi><id>12A5E4E8257155C2B556028FF95ECCC9859A26B3</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/12A5E4E8257155C2B556028FF95ECCC9859A26B3/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/12A5E4E8257155C2B556028FF95ECCC9859A26B3/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/12A5E4E8257155C2B556028FF95ECCC9859A26B3/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Treatment of dysarthria following subthalamic nucleus deep brain stimulation for Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2011</date></publicationStmt><notesStmt><note type="content">*Funding agencies: This research was supported by grants from Parkinson's Disease Society UK (grant 4070), Parkinson's Appeal, Brain Research Trust, Medtronic, and the National Institutes of Health (R01‐NS40902). This work was undertaken at UCLH/UCL, which received a proportion of funding from the UK Department of Health's NIHR Biomedical Research Centres funding scheme.</note><note type="content">*Relevant conflicts of interest/financial disclosures: Nothing to report.</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Treatment of dysarthria following subthalamic nucleus deep brain stimulation for Parkinson's disease</title><author><persName><forename type="first">Elina</forename><surname>Tripoliti</surname></persName><roleName type="degree">PhD</roleName><note type="correspondence"><p>Correspondence: PhD, Unit of Functional Neurosurgery, UCL Institute of Neurology, Box 146, Queen Square, London, WC1N 3BG, UK</p></note><affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</affiliation></author><author><persName><forename type="first">Laura</forename><surname>Strong</surname></persName><roleName type="degree">BSc</roleName><affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</affiliation></author><author><persName><forename type="first">Freya</forename><surname>Hickey</surname></persName><roleName type="degree">BSc</roleName><affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</affiliation></author><author><persName><forename type="first">Tom</forename><surname>Foltynie</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</affiliation></author><author><persName><forename type="first">Ludvic</forename><surname>Zrinzo</surname></persName><affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</affiliation></author><author><persName><forename type="first">Joseph</forename><surname>Candelario</surname></persName><roleName type="degree">BSc</roleName><affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</affiliation></author><author><persName><forename type="first">Marwan</forename><surname>Hariz</surname></persName><roleName type="degree">MD PhD</roleName><affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</affiliation></author><author><persName><forename type="first">Patricia</forename><surname>Limousin</surname></persName><roleName type="degree">MD PhD</roleName><affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-11"></date><biblScope unit="volume">26</biblScope><biblScope unit="issue">13</biblScope><biblScope unit="page" from="2434">2434</biblScope><biblScope unit="page" to="2436">2436</biblScope></imprint></monogr><idno type="istex">12A5E4E8257155C2B556028FF95ECCC9859A26B3</idno><idno type="DOI">10.1002/mds.23887</idno><idno type="ArticleID">MDS23887</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Background:: Deep brain stimulation of the subthalamic nucleus (STN‐DBS) is an established treatment for patients with Parkinson's disease (PD). Speech impairment is a frequent side effect of the surgery. This study examined the efficacy of an intensive speech treatment, the Lee Silverman Voice Treatment (LSVT) on dysarthria after STN‐DBS. Methods:: The LSVT was administered to 10 patients with STN‐DBS (surgical group) and 10 patients without (medical group). Patients were assessed before, immediately after, and 6 months following the speech treatment using sustained phonation, a speech intelligibility scale, and monologue. Vocal loudness, speech intelligibility, and perceptual ratings were the primary outcome measures. Results:: Vocal loudness and perceptual scores improved significantly across tasks for the medical group only. Speech intelligibility did not significantly change for either group. Results in the surgical group were variable, with some patients deteriorating. Conclusions:: Treatment of dysarthria following STN‐DBS needs further investigation because of the variable response to LSVT. © 2011 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>speech</term></item><item><term>LSVT</term></item><item><term>STN‐DBS</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2010-07-14">Received</change><change when="2011-06-29">Registration</change><change when="2011-11">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/12A5E4E8257155C2B556028FF95ECCC9859A26B3/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="130"><doi origin="wiley" registered="yes">10.1002/mds.v26.13</doi><numberingGroup><numbering type="journalVolume" number="26">26</numbering><numbering type="journalIssue">13</numbering></numberingGroup><coverDate startDate="2011-11">November 2011</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="230" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23887</doi><idGroup><id type="unit" value="MDS23887"></id></idGroup><countGroup><count type="pageTotal" number="3"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2011 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2010-07-14"></event><event type="manuscriptRevised" date="2011-06-21"></event><event type="manuscriptAccepted" date="2011-06-29"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.0.1 mode:FullText" date="2011-12-13"></event><event type="publishedOnlineEarlyUnpaginated" date="2011-09-27"></event><event type="publishedOnlineFinalForm" date="2011-11-22"></event><event type="firstOnline" date="2011-09-27"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">2434</numbering><numbering type="pageLast">2436</numbering></numberingGroup><correspondenceTo>PhD, Unit of Functional Neurosurgery, UCL Institute of Neurology, Box 146, Queen Square, London, WC1N 3BG, UK</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23887.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="24"></count><count type="wordTotal" number="3469"></count></countGroup><titleGroup><title type="main" xml:lang="en">Treatment of dysarthria following subthalamic nucleus deep brain stimulation for Parkinson's disease<link href="#fn6"></link><link href="#fn7"></link><link href="#fn8"></link></title><title type="short" xml:lang="en">Speech Treatment Following STN‐DBS</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Elina</givenNames><familyName>Tripoliti</familyName><degrees>PhD</degrees></personName><contactDetails><email>e.tripoliti@ion.ucl.ac.uk</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Laura</givenNames><familyName>Strong</familyName><degrees>BSc</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Freya</givenNames><familyName>Hickey</familyName><degrees>BSc</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Tom</givenNames><familyName>Foltynie</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Ludvic</givenNames><familyName>Zrinzo</familyName></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Joseph</givenNames><familyName>Candelario</familyName><degrees>BSc</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Marwan</givenNames><familyName>Hariz</familyName><degrees>MD PhD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Patricia</givenNames><familyName>Limousin</familyName><degrees>MD PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="GB" type="organization"><unparsedAffiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">speech</keyword><keyword xml:id="kwd3">LSVT</keyword><keyword xml:id="kwd4">STN‐DBS</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><section xml:id="abs1-1"><title type="main">Background:</title><p>Deep brain stimulation of the subthalamic nucleus (STN‐DBS) is an established treatment for patients with Parkinson's disease (PD). Speech impairment is a frequent side effect of the surgery. This study examined the efficacy of an intensive speech treatment, the Lee Silverman Voice Treatment (LSVT) on dysarthria after STN‐DBS.</p></section><section xml:id="abs1-2"><title type="main">Methods:</title><p>The LSVT was administered to 10 patients with STN‐DBS (surgical group) and 10 patients without (medical group). Patients were assessed before, immediately after, and 6 months following the speech treatment using sustained phonation, a speech intelligibility scale, and monologue. Vocal loudness, speech intelligibility, and perceptual ratings were the primary outcome measures.</p></section><section xml:id="abs1-3"><title type="main">Results:</title><p>Vocal loudness and perceptual scores improved significantly across tasks for the medical group only. Speech intelligibility did not significantly change for either group. Results in the surgical group were variable, with some patients deteriorating.</p></section><section xml:id="abs1-4"><title type="main">Conclusions:</title><p>Treatment of dysarthria following STN‐DBS needs further investigation because of the variable response to LSVT. © 2011 Movement Disorder Society</p></section></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn6"><p><b>Funding agencies:</b> This research was supported by grants from Parkinson's Disease Society UK (grant 4070), Parkinson's Appeal, Brain Research Trust, Medtronic, and the National Institutes of Health (R01‐NS40902). This work was undertaken at UCLH/UCL, which received a proportion of funding from the UK Department of Health's NIHR Biomedical Research Centres funding scheme.</p></note><note xml:id="fn7"><p><b>Relevant conflicts of interest/financial disclosures:</b> Nothing to report.</p></note><note xml:id="fn8"><p>Full financial disclosures and author roles may be found in the online version of this article.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Treatment of dysarthria following subthalamic nucleus deep brain stimulation for Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Speech Treatment Following STN‐DBS</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Treatment of dysarthria following subthalamic nucleus deep brain stimulation for Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Elina</namePart><namePart type="family">Tripoliti</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</affiliation><description>Correspondence: PhD, Unit of Functional Neurosurgery, UCL Institute of Neurology, Box 146, Queen Square, London, WC1N 3BG, UK</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Laura</namePart><namePart type="family">Strong</namePart><namePart type="termsOfAddress">BSc</namePart><affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Freya</namePart><namePart type="family">Hickey</namePart><namePart type="termsOfAddress">BSc</namePart><affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Tom</namePart><namePart type="family">Foltynie</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ludvic</namePart><namePart type="family">Zrinzo</namePart><affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Joseph</namePart><namePart type="family">Candelario</namePart><namePart type="termsOfAddress">BSc</namePart><affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Marwan</namePart><namePart type="family">Hariz</namePart><namePart type="termsOfAddress">MD PhD</namePart><affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Patricia</namePart><namePart type="family">Limousin</namePart><namePart type="termsOfAddress">MD PhD</namePart><affiliation>UCL, Institute of Neurology, Sobell Department, Unit of Functional Neurosurgery, Queen Square, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2011-11</dateIssued><dateCaptured encoding="w3cdtf">2010-07-14</dateCaptured><dateValid encoding="w3cdtf">2011-06-29</dateValid><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">2</extent><extent unit="references">24</extent><extent unit="words">3469</extent></physicalDescription><abstract lang="en">Background:: Deep brain stimulation of the subthalamic nucleus (STN‐DBS) is an established treatment for patients with Parkinson's disease (PD). Speech impairment is a frequent side effect of the surgery. This study examined the efficacy of an intensive speech treatment, the Lee Silverman Voice Treatment (LSVT) on dysarthria after STN‐DBS. Methods:: The LSVT was administered to 10 patients with STN‐DBS (surgical group) and 10 patients without (medical group). Patients were assessed before, immediately after, and 6 months following the speech treatment using sustained phonation, a speech intelligibility scale, and monologue. Vocal loudness, speech intelligibility, and perceptual ratings were the primary outcome measures. Results:: Vocal loudness and perceptual scores improved significantly across tasks for the medical group only. Speech intelligibility did not significantly change for either group. Results in the surgical group were variable, with some patients deteriorating. Conclusions:: Treatment of dysarthria following STN‐DBS needs further investigation because of the variable response to LSVT. © 2011 Movement Disorder Society</abstract><note type="content">*Funding agencies: This research was supported by grants from Parkinson's Disease Society UK (grant 4070), Parkinson's Appeal, Brain Research Trust, Medtronic, and the National Institutes of Health (R01‐NS40902). This work was undertaken at UCLH/UCL, which received a proportion of funding from the UK Department of Health's NIHR Biomedical Research Centres funding scheme.</note><note type="content">*Relevant conflicts of interest/financial disclosures: Nothing to report.</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>speech</topic><topic>LSVT</topic><topic>STN‐DBS</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><detail type="issue"><caption>no.</caption><number>13</number></detail><extent unit="pages"><start>2434</start><end>2436</end><total>3</total></extent></part></relatedItem><identifier type="istex">12A5E4E8257155C2B556028FF95ECCC9859A26B3</identifier><identifier type="DOI">10.1002/mds.23887</identifier><identifier type="ArticleID">MDS23887</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2011 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001766 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001766 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:12A5E4E8257155C2B556028FF95ECCC9859A26B3
|texte= Treatment of dysarthria following subthalamic nucleus deep brain stimulation for Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |